Clinical trials have demonstrated that inhaled insulin, administered thrice daily with meals, in addition to controlling post-prandial glucose levels also causes normalization/near-normalization of the fasting plasma glucose (FPG) concentration in patients with type 2 diabetes (T2D) who are inadequately controlled on oral agent therapy [11]. Here, INS is linked to type 2 diabetes mellitus.